A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge

Vaccine

Volumn 30, Issue 30, 2012, Pages 4465-4475

  Reynolds, Matthew R ^a   Weiler, Andrea M ^a   Piaskowski, Shari M ^a   Piatak Jr , Michael ^b   Robertson, Henry T ^c   Allison, David B ^c   Bett, Andrew J ^d   Casimiro, Danilo R ^d   Shiver, John W ^d   Wilson, Nancy A ^a   Lifson, Jeffrey D ^b   Koff, Wayne C ^e   Watkins, David I ^a,f,g  

^a AIDS Vaccine Research Laboratory   (United States)

^b SAIC FREDERICK INC   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus serotype 5; CD4 + T cells; CD8 + T cells; HIV vaccine; Simian immunodeficiency virus; Step trial

Indexed keywords

GAG PROTEIN; GAMMA INTERFERON; NEF PROTEIN; POL PROTEIN; RECOMBINANT ADENOVIRUS SEROTYPE 5 VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CRYOPRESERVATION; DRUG EFFICACY; INFECTION CONTROL; MACACA MULATTA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHESUS IMMUNIZATION; VACCINE FAILURE; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; GENE PRODUCTS, GAG; GENE PRODUCTS, NEF; GENE PRODUCTS, POL; IMMUNITY, CELLULAR; INTERFERON-GAMMA; MACACA MULATTA; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD; VIRUS REPLICATION;

EID: 84862026563     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.082     Document Type: Article

References (68)

1. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893.
2. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis. Lancet 2008, 372:1894-1905.
3. Langford S.E., Ananworanich J., Cooper D.A. Predictors of disease progression in HIV infection: a review. AIDS Research and Therapy 2007, 4:11.
4. Mellors J.W., Margolick J.B., Phair J.P., Rinaldo C.R., Detels R., Jacobson L.P., et al. Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 cell count slope for progression to AIDS and death in untreated HIV-1 infection. The Journal of the American Medical Association 2007, 297:2349-2350.
5. Mellors J.W., Rinaldo C.R.J., Gupta P., White R.M., Todd J.A., Kingsley L.A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
6. Gray R.H., Wawer M.J., Brookmeyer R., Sewankambo N.K., Serwadda D., Wabwire-Mangen F., et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001, 357:1149-1153.
7. Quinn T.C., Wawer M.J., Sewankambo N., Serwadda D., Li C., Wabwire-Mangen F., et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. New England Journal of Medicine 2000, 342:921-929.
8. Cohen J. AIDS research. Did Merck's failed HIV vaccine cause harm?. Science 2007, 318:1048-1049.
9. Fauci A.S., Johnston M.I., Dieffenbach C.W., Burton D.R., Hammer S.M., Hoxie J.A., et al. HIV vaccine research: the way forward. Science 2008, 321:530-532.
10. Sekaly R.P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development. Journal of Experimental Medicine 2008, 205:7-12.
11. Watkins D.I., Burton D.R., Kallas E.G., Moore J.P., Koff W.C. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nature Medicine 2008, 14:617-621.
12. Li F., Finnefrock A.C., Dubey S.A., Korber B.T., Szinger J., Cole S., et al. Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study. PLoS One 2011, 6:e20479.
13. Corey L., McElrath M.J., Kublin J.G. Post-step modifications for research on HIV vaccines. AIDS 2009, 23:3-8.
14. Li F., McKenney D.M., Malhotra U., Crimi C., Nolin J., Corey L., et al. Towards prediction of degenerate CTL epitope recognition. Human Vaccine 2008, 4:115-121.
15. Priddy F.H., Brown D., Kublin J., Monahan K., Wright D.P., Lalezari J., et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clinical Infectious Diseases 2008, 46:1769-1781.
16. Abbink P., Lemckert A.A., Ewald B.A., Lynch D.M., Denholtz M., Smits S., et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. Journal of Virology 2007, 81:4654-4663.
17. Barouch D.H. Novel adenovirus vector-based vaccines for HIV-1. Current Opinion in HIV AIDS 2010, 5:386-390.
18. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002, 415:331-335.
19. Feinberg M.B., Moore J.P. AIDS vaccine models: challenging challenge viruses. Nature Medicine 2002, 8:207-210.
20. Lifson J.D., Martin M.A. One step forwards, one step back. Nature 2002, 415:272-273.
21. Casimiro D.R., Wang F., Schleif W.A., Liang X., Zhang Z.Q., Tobery T.W., et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. Journal of Virology 2005, 79:15547-15555.
22. Casimiro D.R., Cox K., Tang A., Sykes K.J., Feng M., Wang F., et al. Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge. Journal of Virology 2010, 84:2996-3003.
23. Letvin N.L., Mascola J.R., Sun Y., Gorgone D.A., Buzby A.P., Xu L., et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006, 312:1530-1533.
24. Mattapallil J.J., Douek D.C., Buckler-White A., Montefiori D., Letvin N.L., Nabel G.J., et al. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. Journal of Experimental Medicine 2006, 203:1533-1541.
25. Wilson N.A., Reed J., Napoe G.S., Piaskowski S., Szymanski A., Furlott J., et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. Journal of Virology 2006, 80:5875-5885.
26. Fitzgerald D.W., Janes H., Robertson M., Coombs R., Frank I., Gilbert P., et al. An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study). Journal of Infectious Diseases 2011, 203:765-772.
27. Kaslow R.A., Carrington M., Apple R., Park L., Munoz A., Saah A.J., et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nature Medicine 1996, 2:405-411.
28. *08-positive macaques control simian immunodeficiency virus replication. Journal of Virology 2007, 84:1723-1738.
29. *01 is associated with control of simian immunodeficiency virus SIVmac239 replication. Journal of Virology 2003, 77:2736-2740.
30. *17 is associated with control of simian immunodeficiency virus SIVmac239 replication. Journal of Virology 2006, 80:5074-5077.
31. Kaizu M., Borchardt G.J., Glidden C.E., Fisk D.L., Loffredo J.T., Watkins D.I., et al. Molecular typing of major histocompatibility complex class I alleles in the Indian rhesus macaque which restrict SIV CD8+ T cell epitopes. Immunogenetics 2007, 59:693-703.
32. Reynolds M.R., Sacha J.B., Weiler A.M., Borchardt G.J., Glidden C.E., Sheppard N.C., et al. The TRIM5{alpha} genotype of rhesus macaques affects acquisition of simian immunodeficiency virus SIVsmE660 Infection after repeated limiting-dose intrarectal challenge. Journal of Virology 2011, 85:9637-9640.
33. Reynolds M.R., Weiler A.M., Piaskowski S.M., Kolar H.L., Hessell A.J., Weiker M., et al. Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge. Journal of Virology 2010, 84:9190-9199.
34. Cline A.N., Bess J.W., Piatak M., Lifson J.D. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. Journal of Medical Primatology 2005, 34:303-312.
35. Hudgens M.G., Gilbert P.B. Assessing vaccine effects in repeated low-dose challenge experiments. Biometrics 2009, 65:1223-1232.
36. Hudgens M.G., Gilbert P.B., Mascola J.R., Wu C.D., Barouch D.H., Self S.G. Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments. Journal of Infectious Diseases 2009, 200:609-613.
37. Fellay J., Frahm N., Shianna K.V., Cirulli E.T., Casimiro D.R., Robertson M.N., et al. Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial. Journal of Infectious Diseases 2011, 203:773-779.
38. Kirmaier A., Wu F., Newman R.M., Hall L.R., Morgan J.S., O'Connor S., et al. TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biology 2010, 8.
39. Letvin N.L., Rao S.S., Montefiori D.C., Seaman M.S., Sun Y., Lim S.Y., et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Science of Translation Medicine 2011, 3:81ra36.
40. *01 status and TRIM5 allele expression, but not CCL3L copy number variation, to the control of SIVmac251 replication in Indian-origin rhesus monkeys. PLoS Genetics 2010, 6:e1000997.
41. Lim S.Y., Rogers T., Chan T., Whitney J.B., Kim J., Sodroski J., et al. TRIM5alpha modulates immunodeficiency virus control in rhesus monkeys. PLoS Pathogen 2010, 6:e1000738.
42. Yeh W.W., Rao S.S., Lim S.Y., Zhang J., Hraber P.T., Brassard L.M., et al. The TRIM5 gene modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeys. Journal of Virology 2011, 85:10389-10398.
43. Reynolds M.R., Rakasz E., Skinner P.J., White C., Abel K., Ma Z.M., et al. CD8+ T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: too late and too little. Journal of Virology 2005, 79:9228-9235.
44. Reynolds M.R., Weiler A.M., Weisgrau K.L., Piaskowski S.M., Furlott J.R., Weinfurter J.T., et al. Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. Journal of Experimental Medicine 2008, 205:2537-2550.
45. Kiepiela P., Ngumbela K., Thobakgale C., Ramduth D., Honeyborne I., Moodley E., et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nature Medicine 2007, 13:46-53.
46. Liu J., O'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009, 457:87-91.
47. *01-negative rhesus monkeys. Journal of Virology 2005, 79:12321-12331.
48. Bett A.J., Dubey S.A., Mehrotra D.V., Guan L., Long R., Anderson K., et al. Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans. Vaccine 2010, 28:7881-7889.
49. Owen R.E., Sinclair E., Emu B., Heitman J.W., Hirschkorn D.F., Epling C.L., et al. Loss of T cell responses following long-term cryopreservation. Journal of Immunological Methods 2007, 326:93-115.
50. Kreher C.R., Dittrich M.T., Guerkov R., Boehm B.O., Tary-Lehmann M. CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. Journal of Immunological Methods 2003, 278:79-93.
51. Maecker H.T., Moon J., Bhatia S., Ghanekar S.A., Maino V.C., Payne J.K., et al. Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunology 2005, 6:17.
52. Kierstead L.S., Dubey S., Meyer B., Tobery T.W., Mogg R., Fernandez V.R., et al. Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC. AIDS Research and Human Retroviruses 2007, 23:86-92.
53. Rolland M., Tovanabutra S., deCamp A.C., Frahm N., Gilbert P.B., Sanders-Buell E., et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nature Medicine 2011, 17:366-371.
54. Gray G.E., Allen M., Moodie Z., Churchyard G., Bekker L.G., Nchabeleng M., et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infectious Diseases 2011, 11:507-515.
55. Apetrei C., Kaur A., Lerche N.W., Metzger M., Pandrea I., Hardcastle J., et al. Molecular epidemiology of simian immunodeficiency virus SIVsm in U.S. primate centers unravels the origin of SIVmac and SIVstm. Journal of Virology 2005, 79:8991-9005.
56. Gaschen B., Taylor J., Yusim K., Foley B., Gao F., Lang D., et al. Diversity considerations in HIV-1 vaccine selection. Science 2002, 296:2354-2360.
57. Qureshi H., Ma Z.M., Huang Y., Hodge G., Thomas M.A., Dipasquale J., et al. Low dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus 5 then immunized with a replication defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the Phase IIb Step trial of a similar HIV-1 vaccine. Journal of Virology 2012, 86:2239-2250.
58. Fischer W., Perkins S., Theiler J., Bhattacharya T., Yusim K., Funkhouser R., et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nature Medicine 2007, 13:100-106.
59. Koff W.C. Accelerating HIV vaccine development. Nature 2010, 464:161-162.
60. Nickle D.C., Rolland M., Jensen M.A., Pond S.L., Deng W., Seligman M., et al. Coping with viral diversity in HIV vaccine design. PLoS Computation Biology 2007, 3:e75.
61. Shiver J.W., Emini E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annual Review of Medicine 2004, 55:355-372.
62. Jacks T., Power M.D., Masiarz F.R., Luciw P.A., Barr P.J., Varmus H.E. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 1988, 331:280-283.
63. Haynes B. Case control study of the RV144 trial for immune correlates: the analysis and way forward. AIDS Vaccine Conference 2011 2011.
64. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. New England Journal of Medicine 2009, 361:2209-2220.
65. Barouch D.H., Liu J., Li H., Maxfield L.F., Abbink P., Lynch D.M., et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012, 482:89-93.
66. Keele B.F., Li H., Learn G.H., Hraber P., Giorgi E.E., Grayson T., et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. Journal of Experimental Medicine 2009, 206:1117-1134.
67. Wilson N.A., Keele B.F., Reed J.S., Piaskowski S.M., MacNair C.E., Bett A.J., et al. Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. Journal of Virology 2009, 83:6508-6521.
68. Bar KJ, Easlick J, Sun C, Decker J, Sterret S, Li H, et al. Neutralization sensitivity of SIVsmE660 and SIVmac251 challenge stocks and transmitted/founder viruses [abstract]. 28th Annual Symposium on Nonhuman Primate Models; 2010 Oct 19-22; New Orleans, LA. abstract number 6.